Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2009 Oct;8(10):2872–2881. doi: 10.1158/1535-7163.MCT-09-0583

Figure 2. Evaluation of anti-tumor effect and body weight in mice treated with metronomic cyclophosphamide (CTX), OXi-4503 (OXi) or a combination of both drugs.

Figure 2

(A) Tumor volume of nude mice (n=5 per group) othotopically implanted with 231/LM2-4 cells, treated with CTX and OXi-4503.

(B) Body weight of nude mice bearing 231/LM2-4 tumors treated with CTX and OXi-4503 (n=5 per group).

(C) Tumor volume of CB-17 SCID mice (n=5 per group) orthotopically implanted with 231/LM2-4 cells, treated with CTX and OXi-4503.

(D) Nude mice (n=4 per group) subdermally implanted with MeWo cells, treated with CTX and OXi-4503.

Grey arrows, start continuous CTX administration; black arrows, OXi-4503 administration. All error bars + SD. CTX + OXi-4503 values are compared to OXi-4503 alone. * 0.01 < p < 0.05 ; ** p < 0.01 using student’s t-test two-tailed unpaired.